<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04403334</url>
  </required_header>
  <id_info>
    <org_study_id>20180101</org_study_id>
    <nct_id>NCT04403334</nct_id>
  </id_info>
  <brief_title>Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin</brief_title>
  <official_title>Postoperative Safety Outcomes in Patients Undergoing Routine Phacoemulsification Cataract Surgery With Intraoperative Intracameral Injection of Preservative-Free Moxifloxacin Versus Levofloxacin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peregrine Eye and Laser Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peregrine Eye and Laser Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative safety study of intracameral levofloxacin versus moxifloxacin for postoperative
      infection prophylaxis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized clinical trial comparing corneal and retinal changes after intracameral
      levofloxacin or moxifloxacin administered at the end of surgery among eyes undergoing
      uncomplicated phacoemulsification.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Actual">April 28, 2018</completion_date>
  <primary_completion_date type="Actual">April 28, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>unlabelled syringe containing interventional drug</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Cell Count</measure>
    <time_frame>3 months</time_frame>
    <description>Change in endothelial cell count as measured by specular microscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Central Retina Thickness</measure>
    <time_frame>3 months</time_frame>
    <description>Change in central retinal thickness as measured by spectral domain optical coherence tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 months</time_frame>
    <description>Onset of Adverse events following intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Cataract Senile</condition>
  <condition>Endophthalmitis</condition>
  <condition>Antibiotic Side Effect</condition>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>Intracameral levofloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5% unpreserved solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intracameral moxifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5% unpreserved solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin Ophthalmic</intervention_name>
    <description>0.1 ml of unpreserved 0.5% levofloxacin</description>
    <arm_group_label>Intracameral levofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin Ophthalmic</intervention_name>
    <description>0.1 ml of unpreserved 0.5% moxifloxacin</description>
    <arm_group_label>Intracameral moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eyes undergoing uncomplicated cataract surgery by phacoemulsification

        Exclusion Criteria:

          -  Corneal opacities, corneal dystrophies, glaucoma, uveitis, retinopathy, optic
             neuropathy, concomitant infection (blepharitis, hordeolum, or conjunctivitis) or
             uncontrolled systemic disease and intraoperative complications that may affect visual
             outcomes were excluded from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harvey S Uy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peregrine Eye and Laser Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peregrine Eye and Laser Instittute</name>
      <address>
        <city>Makati City</city>
        <state>MM</state>
        <zip>1209</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peregrine Eye and Laser Institute</investigator_affiliation>
    <investigator_full_name>Harvey Siy Uy</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>levofloxacin</keyword>
  <keyword>moxifloxacin</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>endophthalmitis</keyword>
  <keyword>cataract surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endophthalmitis</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

